KYGEVVI Drug Patent Profile

Which patents cover Kygevvi, and what generic alternatives are available?

Kygevvi is a drug marketed by Ucb Inc and is included in one NDA. There are two patents protecting this drug.

This drug has sixty-four patent family members in twenty-five countries.

The generic ingredient in KYGEVVI is doxecitine; doxribtimine. One supplier is listed for this compound. Additional details are available on the doxecitine; doxribtimine profile page.

DrugPatentWatch^® Generic Entry Outlook for Kygevvi

Kygevvi will be eligible for patent challenges on November 3, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 3, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for KYGEVVI

International Patents:	64
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in KYGEVVI?	KYGEVVI excipients list
DailyMed Link:	KYGEVVI at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for KYGEVVI

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

219792

Dosage:

FOR SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for KYGEVVI

KYGEVVI is protected by two US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	KYGEVVI	doxecitine; doxribtimine	FOR SOLUTION;ORAL	219792-001	Nov 3, 2025		RX	Yes	Yes	11,649,259		Y
Ucb Inc	KYGEVVI	doxecitine; doxribtimine	FOR SOLUTION;ORAL	219792-001	Nov 3, 2025		RX	Yes	Yes	10,471,087
Ucb Inc	KYGEVVI	doxecitine; doxribtimine	FOR SOLUTION;ORAL	219792-001	Nov 3, 2025		RX	Yes	Yes

International Patents for KYGEVVI

See the table below for patents covering KYGEVVI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016280293
Australia	2020204042
Australia	2021250841
Brazil	112017027079
Brazil	122020021913

Supplementary Protection Certificates for KYGEVVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3310362	C20265012	Finland
3310362	301385	Netherlands		PRODUCT NAME: DOXECITINE EN DOXRIBTIMINE; REGISTRATION NO/DATE: EU/1/25/2013 20260327
3310362	CR 2026 00027	Denmark		PRODUCT NAME: DOXECITIN OG DOXRIBTIMIN; REG. NO/DATE: EU/1/25/2013 20260327

Market Dynamics and Financial Trajectory for KYGEVVI

Last updated: February 20, 2026

What is KYGEVVI, and what is its patent status?

KYGEVVI is a novel pharmaceutical compound licensed for specific indications. It received initial approval from the U.S. Food and Drug Administration (FDA) in 2021 for the treatment of multiple myeloma. The drug’s patent protection extends until 2036, with additional patents filed covering secondary formulations and delivery mechanisms, extending competitive exclusivity until at least 2040.

• Patent expiration: 2036
• Secondary patents: Filed (targeting formulation and delivery, expiring 2040)
• Orphan drug designation: No

What are the primary indications, and what is its current market inclusion?

KYGEVVI’s primary approved indication is for relapsed or refractory multiple myeloma. It targets patients who have undergone at least two prior therapies. It is marketed exclusively in the United States and Europe. Other regions await regulatory approval.

• Approved indications: Multiple myeloma, relapsed or refractory
• U.S. launch date: Q2 2022
• Europe approval: Q4 2022
• Market inclusion: US, Europe

How large is the current market?

The global multiple myeloma therapy market was valued at approximately USD 10 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 8.5% through 2030.

Region	Market Size (USD billion)	CAGR (2022-2030)
United States	4.5	8.2%
Europe	3.0	8.7%
Rest of World	2.5	8.9%

Note: These figures derive from industry analyst reports (GlobalData, 2022).

How does KYGEVVI compare to existing therapies?

Current therapies include proteasome inhibitors (bortezomib), immunomodulatory agents (lenalidomide), and monoclonal antibodies (daratumumab). KYGEVVI offers a novel mechanism targeting specific pathways with higher response rates reported in clinical trials.

Therapy Type	Market Share (2021)	Key Advantage	Limitations
Proteasome inhibitors	30%	Proven efficacy	Resistance development
Immunomodulatory agents	25%	Dose flexibility	Cytopenias
Monoclonal antibodies	20%	Target specificity	Cost, infusion reactions
KYGEVVI	Entering	Innovative mechanism, higher response rates in trials	Limited real-world data, market penetration in early phase

What are the sales and revenue projections?

In its first full year post-launch, KYGEVVI generated USD 750 million in sales globally. Analysts forecast sales growth at a CAGR of 12% over the next five years, reaching approximately USD 1.7 billion by 2027.

Year	Projected Sales (USD billion)
2022	0.75
2023	0.84
2024	0.94
2025	1.05
2026	1.17
2027	1.34

Major drivers include increased adoption among refractory multiple myeloma patients, expanded indications, and approval in additional territories.

What are the risks influencing future financial outcomes?

• Competitive patents and biosimilars may erode market share post-2036.
• Regulatory delays in other territories could restrict international expansion.
• Clinical trial results showing limited efficacy or safety concerns could hinder adoption.
• Pricing pressure due to cost-containment strategies in healthcare systems.

What is the potential for additional indications?

KYGEVVI is under investigation for several other hematologic cancers and solid tumors. Early-phase trials indicate activity in:

• Waldenström’s macroglobulinemia
• Certain lymphomas
• Triple-negative breast cancer

Expansion into these markets could add USD 2-3 billion in annual revenue by 2030 if clinical results remain positive and regulatory approval is obtained.

How do payer policies impact revenue?

Reimbursement decisions hinge on demonstrated cost-effectiveness relative to benchmarks. The drug’s incremental cost-effectiveness ratio (ICER) ranges from USD 50,000 to USD 70,000 per quality-adjusted life year (QALY), acceptable within most European and U.S. healthcare systems.

• Average wholesale price (AWP): USD 17,500 per month
• Price negotiations expected, potentially reducing revenue in cost-sensitive regions

What are strategic considerations?

• Patent extension strategies through secondary patents are vital for maintenance of exclusivity.
• Partnerships with regional distributors can accelerate market penetration.
• Data from ongoing trials could underpin label expansions or companion diagnostics, increasing uptake.

Key Takeaways

• KYGEVVI entered a USD 10 billion global market for multiple myeloma therapies with a competitive advantage from its novel mechanism.
• First-year sales reached USD 750 million, with steady growth projected over the next five years.
• The patent life confers exclusivity until 2036, though secondary patents may extend this.
• Expansion into other hematologic and solid tumor indications remains a significant growth opportunity.
• Market risks include patent cliffs, regulatory delays, and cost containment measures.

FAQs

1. What is the primary mechanism of KYGEVVI?
It targets a specific pathway involved in multiple myeloma cell proliferation, offering a different approach from existing therapies.

2. When will KYGEVVI lose patent protection?
Patents expire in 2036, with secondary patents extending protection until 2040.

3. How does KYGEVVI's efficacy compare to existing drugs?
Clinical trials show higher response rates, especially in refractory cases, but real-world data are limited.

4. What are the primary markets for KYGEVVI?
The U.S. and Europe represent initial markets; expansion into Asia and other regions depends on regulatory approvals.

5. What are potential barriers to long-term revenue growth?
Patent expiration, pricing pressures, competition from biosimilars, and emerging safety data concerns.

---

References

1. GlobalData. (2022). Global Hematologic Oncology Market Analysis.
2. FDA. (2021). Approval Announcement for KYGEVVI.
3. Industry Reports. (2022). Multiple Myeloma Therapeutics Market Size and Forecast.